In the midst of the COVID-19 pandemic the power of technology has emerged center stage, keeping the industry connected at a time when many ordinary avenues of communication have been cut off over safety concerns. In order to drive forward the next generation of technological and research innovations, we understand how vital it is that industry pioneers are presented with opportunities to continue sharing their research and exchanging insights.
That’s why we set up the Waters Mass Spectrometry Virtual Event 2020. Spanning topics from technological innovations in automation and equipment to the latest research leveraging ion mobility and mass spectrometry, the events were designed to help scientists bring their visions of the future into reality. Read on to discover the fascinating insights that were shared over the course of these sessions! To know more about the topic, click here: https://www.abc.net.au/news/2020-01-21/water-corporation-chairman-michael-hollett-quits-position/11887822
Technological Innovations
Exciting developments in mass spectrometry (MS) technology were an important focus of our virtual event series. Our Andrew Alliance event featured an interesting discussion on the possibilities created by the integration of GlycoWorks, a technology for glycan detection, with the automated Andrew+ pipetting robot. The innovation will enable researchers to obtain more rapid, robust and repeatable results through liquid chromatography-mass spectrometry (LC-MS), while simplifying a complex process. Utilizing the OneLab cloud-native software platform, the modern interface is designed to help combat increasingly cumbersome workflows within pharma and life science through automation.
The ability to design and execute protocols remotely and view their implementation using virtual platforms such as Zoom has been essential during the COVID-19 pandemic. A number of users have had to adapt their workflows ‘on the fly’ and the versatility of the Andrew+ workspace offers real benefits here, given the ease of adding new labware to OneLab and being able to switch in and out of different ontologies, such as shaking and heating/cooling. This is all facilitated within a very compact and flexible footprint, well suited to a biosafety hood.
Solutions to challenges faced by chromatographers were further explored in our Chemistry Seminar. The difficulties inherent in the separation of polar acids using reversed phase (RP) HPLC are well established, with conventional RP columns offering poor retention of acidic analytes. To overcome this challenge, the creation of the Atlantis PREMIER RP/anion-exchange (AX) column was described, which makes use of hybrid organic/inorganic particles and mixed-mode bonding, as well as new MaxPeakTM High Performance Surface column hardware to improve reproducibility and reduce analyte losses. By combining the power of the two technologies, researchers are presented with a solution to a complex challenge that has plagued many generations of scientists.
This theme of utilizing the latest technological advancements to solve long-standing challenges was also expanded on in our Advanced Mass Spectrometry Technology (AMST) seminar, which focused on the exciting possibilities combining Electron Capture Dissociation (ECD) in the SELECT SERIES Cyclic IMS. Featuring a cyclic path length, this instrument enables scalable, ultra-high resolution ion mobility-mass spectrometry (IMS-MS), giving researchers the ability to investigate molecular structure like never before. By merging the capabilities of the Cyclic IMS with ECD, the AMST Seminar delved into the potential for improved structural analysis of peptides, intact proteins and protein complexes. This has exciting implications for research focused on understanding disease mechanisms and uncovering new drug treatments, and highlights the importance of continuing to expand on the features of cutting-edge instrumentation.
Latest Research Utilizing Ion Mobility
Another key focus of our virtual event series was breakthroughs in ion mobility-mass spectrometry technology that are paving the way for new discoveries. Our Advanced Mass Spectrometry Technology (AMST) Symposium shed light on the biomedical research applications of the SELECT SERIES Cyclic IMS and SYNAPT XS, our latest high-resolution IMS-MS instruments. The talks given at the symposium underscored the value of combining advanced ion mobility separation with MS for elucidating complex data that contains insights into cellular processes and mechanisms. In addition, the power of MS imaging technology for spatially mapping disease biomarkers was also highlighted. Moving forward, discussions held at the event emphasized the value of the sensitivity and high-throughput of DESI imaging for clinical research, and described how further development of chemical databases and software will help launch the technique into new application areas.
Among the application areas that IMS-MS promises to drive forward are petroleomics and chemical manufacturing – topics that were explored in depth at our Chemical & Materials Symposium. Petroleum samples comprise highly complex mixtures that can often be difficult to accurately interpret and assign structures to. A talk held at the event highlighted how the latest Cyclic IMS instrument rose to the challenge in a study of petroleum mixtures, providing insights into its polluting aspects through its advanced separation capabilities. In addition, the application of IMS-MS for troubleshooting issues at chemical plants, such as solid formation, by providing improved structural elucidation was discussed. In future, it is anticipated that IMS-MS will increasingly help to develop, manufacture and characterize advanced materials.
Our Pharma Seminar, meanwhile, delved into the use of IMS-MS and collision cross section (CCS) values for analyzing structurally complex cyclic peptides containing natural and unnatural modifications when performing metabolite identification. The incorporation of these types of modifications is a common strategy to improve the efficacy and absorption, distribution, metabolism and excretion (ADME) profile of peptide therapeutics. Making use of Mass-MetaSite and WebMetabase software combined with IMS-MS, researchers were able to process the information-rich data and rapidly determine the metabolic fate of candidate compounds, helping to inform the design of drug candidates with improved pharmacokinetic properties.
Altogether, the Pharma Seminar shined a light on the value of fusing advanced software with high-resolution analytical technologies. As the trend for increasingly complex drug targets and drug molecules continues, this important insight can help scientists accelerate their drug discovery and development research to deliver effective therapeutic treatments.